Literature DB >> 35051942

MicroRNAs in Obesity-Associated Disorders: The Role of Exercise Training.

Andre Silveira1,2, João Gomes1, Fernanda Roque1, Tiago Fernandes1, Edilamar Menezes de Oliveira1.   

Abstract

Obesity is a worldwide epidemic affecting over 13% of the adult population and is defined by an excess of body fat that predisposes comorbidities. It is considered a multifactorial disease in which environmental and genetic factors interact, and it is a risk marker for cardiovascular disease. Lifestyle modifications remain the mainstay of treatment for obesity based on adequate diet and physical exercise. In addition, obesity is related to cardiovascular and skeletal muscle disorders, such as cardiac hypertrophy, microvascular rarefaction, and skeletal muscle atrophy. The discovery of obesity-involved molecular pathways is an important step to improve both the prevention and management of this disease. MicroRNAs (miRNAs) are a class of gene regulators which bind most commonly, but not exclusively, to the 3'-untranslated regions of messenger RNAs of protein-coding genes and negatively regulate their expression. Considerable effort has been made to identify miRNAs and target genes that predispose to obesity. Besides their intracellular function, recent studies have demonstrated that miRNAs can be exported or released by cells and circulate within the blood in a remarkably stable form. The discovery of circulating miRNAs opens up intriguing possibilities for the use of circulating miRNA patterns as biomarkers for obesity and cardiovascular diseases. The aim of this review is to provide an overview of the recent discoveries of the role played by miRNAs in the obese phenotype and associated comorbidities. Furthermore, we will discuss the role of exercise training on regulating miRNAs, indicating the mechanisms related to these alterations.
© 2022 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Biomarker; Cardiac hypertrophy; Exercise training; MicroRNA; Microvascular rarefaction; Obesity

Mesh:

Substances:

Year:  2022        PMID: 35051942      PMCID: PMC9021631          DOI: 10.1159/000517849

Source DB:  PubMed          Journal:  Obes Facts        ISSN: 1662-4025            Impact factor:   4.807


  106 in total

1.  Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation.

Authors:  Rumiko Ogawa; Chie Tanaka; Masahiro Sato; Haruka Nagasaki; Kazuto Sugimura; Katsuzumi Okumura; Yoshimi Nakagawa; Naohito Aoki
Journal:  Biochem Biophys Res Commun       Date:  2010-07-17       Impact factor: 3.575

2.  Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children.

Authors:  Abdelnaby Khalyfa; Leila Kheirandish-Gozal; Rakesh Bhattacharjee; Ahamed A Khalyfa; David Gozal
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

3.  Adipose tissue extracellular matrix and vascular abnormalities in obesity and insulin resistance.

Authors:  Michael Spencer; Resat Unal; Beibei Zhu; Neda Rasouli; Robert E McGehee; Charlotte A Peterson; Philip A Kern
Journal:  J Clin Endocrinol Metab       Date:  2011-10-12       Impact factor: 5.958

4.  miR-519d overexpression is associated with human obesity.

Authors:  Rosanna Martinelli; Carmela Nardelli; Vincenzo Pilone; Tonia Buonomo; Rosario Liguori; Ilenia Castanò; Pasqualina Buono; Stefania Masone; Giovanni Persico; Pietro Forestieri; Lucio Pastore; Lucia Sacchetti
Journal:  Obesity (Silver Spring)       Date:  2010-01-07       Impact factor: 5.002

5.  MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation.

Authors:  Francisco J Ortega; José M Moreno-Navarrete; Gerard Pardo; Monica Sabater; Manuela Hummel; Anna Ferrer; Jose I Rodriguez-Hermosa; Bartomeu Ruiz; Wifredo Ricart; Belen Peral; José M Fernández-Real
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

6.  Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation.

Authors:  Naomi Hosogai; Atsunori Fukuhara; Kazuya Oshima; Yugo Miyata; Sachiyo Tanaka; Katsumori Segawa; Shigetada Furukawa; Yoshihiro Tochino; Ryutaro Komuro; Morihiro Matsuda; Iichiro Shimomura
Journal:  Diabetes       Date:  2007-04       Impact factor: 9.461

7.  Body mass index and vigorous physical activity and the risk of heart failure among men.

Authors:  Satish Kenchaiah; Howard D Sesso; J Michael Gaziano
Journal:  Circulation       Date:  2008-12-22       Impact factor: 29.690

8.  Effects of physical exercise on the P38MAPK/REDD1/14-3-3 pathways in the myocardium of diet-induced obesity rats.

Authors:  B L S Pieri; D R Souza; T F Luciano; S O Marques; J R Pauli; A S R Silva; E R Ropelle; R A Pinho; F S Lira; C T De Souza
Journal:  Horm Metab Res       Date:  2014-04-01       Impact factor: 2.936

9.  Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease.

Authors:  Sarah C Ferrante; Evan P Nadler; Dinesh K Pillai; Monica J Hubal; Zuyi Wang; Justin M Wang; Heather Gordish-Dressman; Emily Koeck; Samantha Sevilla; Andrew A Wiles; Robert J Freishtat
Journal:  Pediatr Res       Date:  2014-12-17       Impact factor: 3.756

10.  miR-148a is Associated with Obesity and Modulates Adipocyte Differentiation of Mesenchymal Stem Cells through Wnt Signaling.

Authors:  Chunmei Shi; Min Zhang; Meiling Tong; Lei Yang; Lingxia Pang; Ling Chen; Guangfeng Xu; Xia Chi; Qin Hong; Yuhui Ni; Chenbo Ji; Xirong Guo
Journal:  Sci Rep       Date:  2015-05-22       Impact factor: 4.379

View more
  2 in total

Review 1.  Sex Differences in Biological Systems and the Conundrum of Menopause: Potential Commonalities in Post-Menopausal Disease Mechanisms.

Authors:  David A Hart
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

2.  Approach to Patients with Obesity and Other Cardiovascular Risk Factors in Primary Care Using the Delphi Methodology.

Authors:  Pedro Morillas Blasco; Silvia Gómez Moreno; Tomás Febles Palenzuela; Vicente Pallarés Carratalá
Journal:  J Clin Med       Date:  2022-07-16       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.